Consolidated Financial Results for the Three Months Ended June 30, 2026〔IFRS〕
Filed with TSE · · 20 pages · English
(Note) Revision from the dividend guidance published most recently: None 3. Consolidated Financial Guidance for the Fiscal Year Ending March 31, 2027 (from April 1, 2026 to March 31, 2027) (Note 1) Revision of guidance published most recently: Yes Please refer to the “Notice Concerning Revisions to Full-Year Consolidated Financial Guidance for Fiscal Year Ending March 31, 2027 (FY2026)” released o
In the deck
Story so far
Earlier from Terumo
- Notice Concerning the Determination of Details of Issuance of Stock Options (Share Warrants)
- Notice Regarding Disposal of Treasury Shares as Restricted Stock Remuneration
- Terumo Announces Voluntary Recall of Specific Models of the Relay™Pro Thoracic Stent-Graft System in Global Markets
- Terumo Interventional Systems Announces First Procedure Using Its OPUSWAVE® Dual Sensor Imaging System in the United States
- Financial Results for the Fiscal Year Ended March 31, 2026 (FY2025)(with note)
Later from Terumo
- Notice Concerning Change in Subsidiary
- Terumo Neuro Announces Two WISE Study Publications Reporting 0% New Bleeds or Rebleeds Through One Year Following WEB™ Treatment in Ruptured and Unruptured Aneurysm Cohorts
- 6 countries across Terumo Asia Pacific officially recognized as Best Workplaces™ Certified by Great Place To Work®
- Notice Concerning Recognition of Losses Resulting from the Termination of a Supply Agreement with a Major Customer and the Revision of Consolidated Fi
- Decision Regarding the Termination of the Supply Agreement with CSL Plasma (with note)
Follow Terumo into a list and get an email when it puts out news.
Follow Terumo